Premium
Neuroprotective effects of an engineered commensal bacterium in the 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine Parkinson disease mouse model via producing glucagon‐like peptide‐1
Author(s) -
Fang Xin,
Tian Puyuan,
Zhao Xiaoxiao,
Jiang Chunling,
Chen Tingtao
Publication year - 2019
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/jnc.14694
Subject(s) - mptp , parkinson's disease , neuroprotection , tyrosine hydroxylase , akkermansia , glucagon like peptide 1 , endocrinology , dopamine , medicine , pharmacology , biology , disease , biochemistry , diabetes mellitus , lactobacillus , type 2 diabetes , fermentation
While glucagon‐like peptide‐1 ( GLP ‐1) was reported to have a positive impact on Parkinson disease, it is extremely short half‐life greatly hindered its clinical use. In this study, the mouse strain MG 1363‐ pMG 36e‐ GLP ‐1 was engineered to continuously express GLP ‐1 to treat Parkinson disease in a 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine ( MPTP )‐treated Parkinson disease model. In our study, oral supplementation with MG 1363‐ pMG 36e‐ GLP ‐1 significantly ( p < 0.05) reduced MPTP ‐induced locomotor impairments, increased tyrosine hydroxylase‐positive neurons, suppressed microglia and astrocyte activation, and down‐regulated expression of several inflammation‐related molecules. In addition, MG 1363‐ pMG 36e‐ GLP ‐1 significantly ( p < 0.01) reduced intestinal pathogen Enterobacteriaceae and markedly enhanced the number of probiotic Lactobacillus and Akkermansia . These data suggest that MG 1363‐ pMG 36e‐ GLP ‐1 could be a novel therapeutic means for Parkinson disease.